AST 120 clinical trials
How each study uses AST 120 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AST 120 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2007 (7)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 7 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 6
Ocera Therapeutics (7) · Tanabe Pharma Corporation (2) · Astellas Pharma Inc (2) · Chang Gung Memorial Hospital (2) · Conmed Pharmaceutical & Bio-Medical Corporation (1) · Tungs' Taichung Metroharbour Hospital (1) · Seoul National University Hospital (1) · Institute for Health Outcomes and Process Evaluation Reseach (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test AST 120.
- Feb 2027AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney DiseasePhase 4 · Chang Gung Memorial Hospital
Studies
Open first, then newest update. How each study uses AST 120 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney DiseaseRecruitingPhase 4Chang Gung Memorial HospitalNCT07182422Written as AST-120 (Kremezin®)How we know
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)CompletedPhase 3Tanabe Pharma CorporationNCT00500682Written as AST-120How we know
- A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)CompletedPhase 3Tanabe Pharma CorporationNCT00501046Written as AST-120How we know
- AST-120 in Hemodialysis Patients With Uremic PruritusCompletedPhase 4Conmed Pharmaceutical & Bio-Medical CorporationNCT04639674Written as AST-120How we know
- Pharmacokinetic Study of ASP1517 With Kremezin®CompletedPhase 1Astellas Pharma IncNCT02693613Written as Kremezin®How we know
- Safety and Efficacy of AST-120 in the Treatment of PouchitisCompletedPhase 2Ocera TherapeuticsNCT00583076Written as AST-120How we know
- Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel SyndromeCompletedPhase 2Ocera TherapeuticsNCT00583128Written as AST-120How we know
- AST-120 Used to Treat Mild Hepatic EncephalopathyCompletedPhase 2Ocera TherapeuticsNCT00867698Written as AST-120How we know
- Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory PouchitisTerminatedPhase 2Ocera TherapeuticsNCT00583531Written as AST-120How we know
- Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPITerminatedPhase 2Ocera TherapeuticsNCT00587275Written as AST-120How we know
- Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With FistulasCompletedPhase 3Ocera TherapeuticsNCT00321412Written as AST-120How we know
- Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic EncephalopathyCompletedPhase 2Ocera TherapeuticsNCT00558038Written as AST-120How we know
- Effect of Replacement Volume of Haemodiafiltration and AST-120 on Toxins, Oxidative Stress and MicroInflammationCompletedPhase 4Tungs' Taichung Metroharbour HospitalNCT01458652Written as KremezinHow we know
- Kremezin Study Against Renal Disease Progression in KoreaCompletedPhase 4Seoul National University HospitalNCT00860431Written as AST-120How we know
- Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.CompletedPhase 4Chang Gung Memorial HospitalNCT01681303Written as AST-120How we know
- The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney DiseaseStatus unknownPhase 4Ewha Womans UniversityNCT01157260Written as KremezinHow we know
- Drug-Drug Interaction Study of TRK-100STPCompletedPhase 1Astellas Pharma IncNCT00719758Written as AST-120 (Kremezin®)How we know
- Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney DiseaseCompletedPhase 4Institute for Health Outcomes and Process Evaluation ReseachNCT00456859Written as KremezinHow we know
Codes
What other systems call AST 120 · ClinicalTrials.gg INT003137
- MeSH (NLM) C040896AST 120One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C040896 | AST 120 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.